Abstract:Objective To investigate the value of combined application of MDM2,CDK4 and SATB2 immunohistochemistry in pathological diagnosis of low-grade osteosarcoma.Methods Forty-seven cases of low grade osteosarcoma,including low grade central osteosarcoma (n =20) and parosteal osteosarcoma (n =27),were selected from Shanghai Jiaotong University Affiliated the Sixth People' s Hospital.The clinical,radiography and histopathology were reviewed.The sensitivity and specificity of MDM2,CDK4 and SATB2 immunohistochemistry in the diagnosis of low-grade osteosarcoma were assessed along with an evaluation of their expressions in fibrous dysplasia,desmoplastic fibroma,low-grade fibrosarcoma and other fibrous tumors.Results Low-grade osteosarcoma had protracted clinical course,occurring mostly in elder adults and mainly involving long bones.Radiographic studies showed that low-grade central osteosarcoma had a mainly malignant lytic presentation,however about 5/18 of tumors overlapping with intermediate and benign bone diseases,while parosteal osteosarcoma was characterized by a densely sclerotic malignant appearance.Histologically,low-grade osteosarcomas were characterized by well-differentiated spindle tumor cells,various mature tumor bones and an aggressive growth pattern.The positive expression rates of MDM2 and CDK4 in low-grade osteosarcoma were 74.5％ and 55.3％,respectively.Eighty-three percent of low-grade osteosarcoma expressed one or both markers.Low-grade osteosarcoma and fibrous dysplasia were both positive for SATB2,while desmoplastic fibroma,low-grade fibrosacoma and other fibrous tumors were negative for SATB2.Conclusions Accurate diagnosis of low-grade osteosarcoma should be based on combination of clinical presentation,imaging and histopathology,with immunohistochemistry as a diagnostic adjunct.Positive immunostaining for CDK4 and/or MDM2 supports the diagnosis of low-grade osteosarcoma,but the negative one does not rule out such lesion.The negative expression of SATB2 is helpful to exclude fibrous tumors originating from bone with the exception of fibrous dysplasia.

Special AT-rich sequence-binding protein 2 immunohistochemistry in the diagnosis of osteosarcoma in dogs

Immunohistochemical Investigation into Protein Expression Patterns of FOXO4, IRF8 and LEF1 in Canine Osteosarcoma

LncRNA SATB2-AS1 Promotes Tumor Growth and Metastasis and Affects the Tumor Immune Microenvironment in Osteosarcoma by Regulating SATB2

Molecular Characterisation of Canine Osteosarcoma in High Risk Breeds

Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray

Transcriptomic Analysis of Canine Osteosarcoma from a Precision Medicine Perspective Reveals Limitations of Differential Gene Expression Studies

Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma

SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma

Characterization of expression and prognostic implications of transforming growth factor beta, programmed death-ligand 1, and T regulatory cells in canine histiocytic sarcoma

Evaluation of SOX-10 immunohistochemical expression in canine melanoma and non-melanocytic tumors by tissue microarray

It's not always histiocytic sarcoma: Immunocytochemistry to identify two unusual tumors in a Bernese Mountain dog

Large Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes

Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma

Meta-analysis of SATB2 immunohistochemical expression in colorectal cancer versus primary ovarian mucinous neoplasms

Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases

Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors

A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs

Investigating Cox-2 and EGFR as Biomarkers in Canine Oral Squamous Cell Carcinoma: Implications for Diagnosis and Therapy

Inhibitory checkpoint molecule mRNA expression in canine soft tissue sarcoma

Satb2 Is A Sensitive Marker For Lower Gastrointestinal Well-Differentiated Neuroendocrine Tumors

Proteomic profiling of osteosarcoma cells identifies ALDOA and SULT1A3 as negative survival markers of human osteosarcoma.